We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.


New Trading Tool: Live US Options Flow! Try it out.

SAN Sanofi

-0.40 (-0.39%)
22 Sep 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Share Name Share Symbol Market Type
Sanofi EU:SAN Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40 -0.39% 102.10 101.00 102.50 102.38 100.78 101.76 1,522,223 16:40:00

Sanofi Shares Rise After Dupixent Trial Hits Targets, Adding to Drug Potential

23/03/2023 11:08am

Dow Jones News

Sanofi (EU:SAN)
Historical Stock Chart

From Sep 2022 to Sep 2023

Click Here for more Sanofi Charts.

By Adria Calatayud


Shares in Sanofi SA rose Thursday after the French pharmaceutical company and Regeneron Pharmaceuticals Inc. said their jointly developed Dupixent drug showed potential to treat chronic obstructive pulmonary disease in a late-stage trial.

At 1034 GMT, Sanofi shares traded 5% higher at 95.38 euros ($103.44).

Sanofi and Regeneron said Dupixent met the primary and all key secondary objectives in a Phase 3 trial, and that this made it the first biologic to show clinically meaningful reduction in exacerbations of COPD, as well as significant improvements in lung function, compared to placebo.

Patients who received the drug in the trial experienced a 30% reduction in moderate or severe acute COPD exacerbations over 52 weeks, the companies said.

This is the seventh disease against which Dupixent has shown positive results, Sanofi and Regeneron said. The companies jointly developed the drug under a global collaboration agreement.

Analysts at Jefferies said in a research note that results from the trial suggest Dupixent has blockbuster potential as a COPD treatment, a challenging indication for which no biologic had shown benefits to date despite numerous attempts.


Write to Adria Calatayud at adria.calatayud@dowjones.com


(END) Dow Jones Newswires

March 23, 2023 06:53 ET (10:53 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

1 Year Sanofi Chart

1 Year Sanofi Chart

1 Month Sanofi Chart

1 Month Sanofi Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: gb D: 20230924 00:17:59